{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:44:44Z","timestamp":1789796684266,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,14]]},"DOI":"10.7759\/cureus.29167","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T20:23:31Z","timestamp":1663187011000},"source":"Crossref","is-referenced-by-count":15,"title":["The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry"],"prefix":"10.7759","author":[{"given":"Joshua S","family":"Kurtz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal A","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian L","family":"Gendreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolan","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce","family":"Picton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sahyouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Daniel","family":"Diaz-Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mickey E","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"U.S. FDA. Cesamet\u2122. (2016). Accessed. July 8, 2022: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/018677s011lbl.pdf."},{"key":"ref2","unstructured":"Switzerland Briefly Legalized LSD Therapy and Then Couldn't Let It Go. (2015). Accessed. July 8, 2022: https:\/\/www.vice.com\/en\/article\/aekz8g\/switzerland-briefly-legalized-lsd-therapy-and-then-couldnt-let-it-go."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron LP","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, et al.. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021, 589:474-9. 10.1038\/s41586-020-3008-z","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, et al.. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016, 3:619-27. 10.1016\/S2215-0366(16)30065-7","journal-title":"Lancet Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris RL","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, et al.. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012, 109:2138-43. 10.1073\/pnas.1119598109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017, 42:2105-13. 10.1038\/npp.2017.84","journal-title":"Neuropsychopharmacology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291715002901","article-title":"The paradoxical psychological effects of lysergic acid diethylamide (LSD)","volume":"46","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Kaelen M, Bolstridge M, et al.. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016, 46:1379-90. 10.1017\/S0033291715002901","journal-title":"Psychol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3714-z","article-title":"LSD enhances suggestibility in healthy volunteers","volume":"232","author":"Carhart-Harris RL","year":"2015","unstructured":"Carhart-Harris RL, Kaelen M, Whalley MG, Bolstridge M, Feilding A, Nutt DJ. LSD enhances suggestibility in healthy volunteers. Psychopharmacology (Berl). 2015, 232:785-94. 10.1007\/s00213-014-3714-z","journal-title":"Psychopharmacology (Berl)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al.. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016, 113:4853-8. 10.1073\/pnas.1518377113","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-007-0930-9","article-title":"Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans","volume":"195","author":"Carter OL","year":"2007","unstructured":"Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX. Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl). 2007, 195:415-24. 10.1007\/s00213-007-0930-9","journal-title":"Psychopharmacology (Berl)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116715","article-title":"A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses","volume":"411","author":"Chi T","year":"2020","unstructured":"Chi T, Gold JA. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. J Neurol Sci. 2020, 411:116715. 10.1016\/j.jns.2020.116715","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/0269881109103227","article-title":"Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis","volume":"24","author":"Daumann J","year":"2010","unstructured":"Daumann J, Wagner D, Heekeren K, Neukirch A, Thiel CM, Gouzoulis-Mayfrank E. Neuronal correlates of visual and auditory alertness in the DMT and ketamine model of psychosis. J Psychopharmacol. 2010, 24:1515-24. 10.1177\/0269881109103227","journal-title":"J Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1177\/2045125316689030","article-title":"Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies","volume":"7","author":"Dos Santos RG","year":"2017","unstructured":"Dos Santos RG, Bouso JC, Hallak JE. Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. Ther Adv Psychopharmacol. 2017, 7:141-57. 10.1177\/2045125316689030","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi HR","year":"2005","unstructured":"El-Seedi HR, De Smet PA, Beck O, Possnert G, Bruhn JG. Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas. J Ethnopharmacol. 2005, 101:238-42. 10.1016\/j.jep.2005.04.022","journal-title":"J Ethnopharmacol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000084","article-title":"Clinical applications of hallucinogens: a review","volume":"24","author":"Garcia-Romeu A","year":"2016","unstructured":"Garcia-Romeu A, Kersgaard B, Addy PH. Clinical applications of hallucinogens: a review. Exp Clin Psychopharmacol. 2016, 24:229-68. 10.1037\/pha0000084","journal-title":"Exp Clin Psychopharmacol"},{"key":"ref16","unstructured":"Research Update. Psychedelic Group Therapy in Switzerland. (2017). Accessed: July 8, 2022: https:\/\/maps.org\/news\/bulletin\/research-update-psychedelic-group-therapy-in-switzerland\/."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-916185","article-title":"Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers","volume":"38","author":"Gouzoulis-Mayfrank E","year":"2005","unstructured":"Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar KA. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005, 38:301-11. 10.1055\/s-2005-916185","journal-title":"Pharmacopsychiatry"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, et al.. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016, 30:1181-97. 10.1177\/0269881116675513","journal-title":"J Psychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0457-5","article-title":"Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance","volume":"187","author":"Griffiths RR","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl). 2006, 187:268-83; discussion 284-92. 10.1007\/s00213-006-0457-5","journal-title":"Psychopharmacology (Berl)"},{"key":"ref20","article-title":"Psychedelic Drugs Reconsidered","author":"Grinspoon L","year":"1979","unstructured":"Grinspoon L, Bakalar JB. Psychedelic Drugs Reconsidered. Basic Books, New York; 1979."},{"key":"ref21","article-title":"Psychiatric research with hallucinogens: What have we learned?","author":"Grob C","year":"1994","unstructured":"Grob C. Psychiatric research with hallucinogens: What have we learned? . Yearbook for Ethnomedicine and the Study of Consciousness. Verlag fur Wissenschaft und Bildung, Berlin; 1994."},{"key":"ref22","article-title":"LSD Psychotherapy","author":"Grof S","year":"2001","unstructured":"Grof S. LSD Psychotherapy. San Jose, CA (ed): Multidisciplinary Association for Psychedelic Studies, 2001."},{"key":"ref23","unstructured":"Basel in the spolight. the city that learned to love LSD. (2018). Accessed: July 12, 2022: https:\/\/www.theguardian.com\/cities\/2018\/apr\/19\/basel-in-the-spotlight-the-city-that-learned-to-love-lsd-albert-hofmann."},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/cber.18960290145","article-title":"Berichte der deutschen chemischen Gesellschaft","volume":"29","author":"Heffter A","year":"1896","unstructured":"Heffter A. Berichte der deutschen chemischen Gesellschaft. Ueber Cateenalkalo\u00efde. 1896, 29:216-27. 10.1002\/cber.18960290145","journal-title":"Ueber Cateenalkalo\u00efde"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/BF02159243","article-title":"[Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim] [Article in German]","volume":"14","author":"Hofmann A","year":"1958","unstructured":"Hofmann A, Heim R, Brack A, Kobel H. [Psilocybin, a psychotropic substance from the Mexican mushroom Psilicybe mexicana Heim] [Article in German]. Experientia. 1958, 14:107-9. 10.1007\/BF02159243","journal-title":"Experientia"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/molecules20022208","article-title":"The anti-addiction drug ibogaine and the heart: a delicate relation","volume":"20","author":"Koenig X","year":"2015","unstructured":"Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015, 20:2208-28. 10.3390\/molecules20022208","journal-title":"Molecules"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2012.04.005","article-title":"Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors","volume":"72","author":"Kometer M","year":"2012","unstructured":"Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Psilocybin biases facial recognition, goal-directed behavior, and mood state toward positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry. 2012, 72:898-906. 10.1016\/j.biopsych.2012.04.005","journal-title":"Biol Psychiatry"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116675755","article-title":"Back to the future: research renewed on the clinical utility of psychedelic drugs","volume":"30","author":"Lieberman JA","year":"2016","unstructured":"Lieberman JA, Shalev D. Back to the future: research renewed on the clinical utility of psychedelic drugs. J Psychopharmacol. 2016, 30:1198-200. 10.1177\/0269881116675755","journal-title":"J Psychopharmacol"},{"key":"ref29","article-title":"LSD treatment in alcoholism","author":"Ludwig AM","year":"1970","unstructured":"Ludwig AM. LSD treatment in alcoholism. Hallucinogenic\u00a0Drug\u00a0Research:\u00a0Impact\u00a0on\u00a0Science\u00a0and\u00a0Society. Gamage\u00a0JR, Zerkin EL (ed): Stash\u00a0Press, Beloit, WI; 1970."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111420188","article-title":"Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness","volume":"25","author":"MacLean KA","year":"2011","unstructured":"MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. J Psychopharmacol. 2011, 25:1453-61. 10.1177\/0269881111420188","journal-title":"J Psychopharmacol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.118.543.229","article-title":"Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom","volume":"118","author":"Malleson N","year":"1971","unstructured":"Malleson N. Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry. 1971, 118:229-30. 10.1192\/bjp.118.543.229","journal-title":"Br J Psychiatry"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial","volume":"5","author":"Mithoefer MC","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, et al.. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry. 2018, 5:486-97. 10.1016\/S2215-0366(18)30135-4","journal-title":"Lancet Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer MC","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011, 25:439-52. 10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2063-13.2013","article-title":"Broadband cortical desynchronization underlies the human psychedelic state","volume":"33","author":"Muthukumaraswamy SD","year":"2013","unstructured":"Muthukumaraswamy SD, Carhart-Harris RL, Moran RJ, et al.. Broadband cortical desynchronization underlies the human psychedelic state. J Neurosci. 2013, 33:15171-83. 10.1523\/JNEUROSCI.2063-13.2013","journal-title":"J Neurosci"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.17226\/24625","article-title":"The\u00a0Health\u00a0Effects\u00a0of\u00a0Cannabis\u00a0and\u00a0Cannabinoids:\u00a0The\u00a0Current\u00a0State\u00a0of\u00a0Evidence\u00a0and\u00a0Recommendations\u00a0for\u00a0Research","author":"National Academies of Sciences","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. The\u00a0Health\u00a0Effects\u00a0of\u00a0Cannabis\u00a0and\u00a0Cannabinoids:\u00a0The\u00a0Current\u00a0State\u00a0of\u00a0Evidence\u00a0and\u00a0Recommendations\u00a0for\u00a0Research. National Academies\u00a0Press, Washington, DC; 2017. 10.17226\/24625"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt D","year":"2007","unstructured":"Nutt D, King LA, Saulsbury W, Blakemore C. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet. 2007, 369:1047-53. 10.1016\/S0140-6736(07)60464-4","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt DJ","year":"2013","unstructured":"Nutt DJ, King LA, Nichols DE. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci. 2013, 14:577-85. 10.1038\/nrn3530","journal-title":"Nat Rev Neurosci"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt DJ","year":"2010","unstructured":"Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010, 376:1558-65. 10.1016\/S0140-6736(10)61462-6","journal-title":"Lancet"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/jhmas\/jrs050","article-title":"Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962","volume":"69","author":"Oram M","year":"2014","unstructured":"Oram M. Efficacy and enlightenment: LSD psychotherapy and the Drug Amendments of 1962. J Hist Med Allied Sci. 2014, 69:221-50. 10.1093\/jhmas\/jrs050","journal-title":"J Hist Med Allied Sci"},{"key":"ref40","unstructured":"Overdose Death Rates. (2021). Accessed. July 8, 2022: https:\/\/www.drugabuse.gov\/drug-topics\/trends-statistics\/overdose-death-rates."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118143","article-title":"The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network","volume":"10","author":"Palhano-Fontes F","year":"2015","unstructured":"Palhano-Fontes F, Andrade KC, Tofoli LF, et al.. The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network. PLoS One. 2015, 10:e0118143. 10.1371\/journal.pone.0118143","journal-title":"PLoS One"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2016.12.030","article-title":"The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation","volume":"27","author":"Preller KH","year":"2017","unstructured":"Preller KH, Herdener M, Pokorny T, et al.. The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol. 2017, 27:451-7. 10.1016\/j.cub.2016.12.030","journal-title":"Curr Biol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000077946","article-title":"Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography","volume":"50","author":"Riba J","year":"2004","unstructured":"Riba J, Anderer P, Jan\u00e9 F, Saletu B, Barbanoj MJ. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography. Neuropsychobiology. 2004, 50:89-101. 10.1159\/000077946","journal-title":"Neuropsychobiology"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0358-7","article-title":"Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant","volume":"186","author":"Riba J","year":"2006","unstructured":"Riba J, Romero S, Grasa E, Mena E, Carri\u00f3 I, Barbanoj MJ. Increased frontal and paralimbic activation following ayahuasca, the pan-Amazonian inebriant. Psychopharmacology (Berl). 2006, 186:93-8. 10.1007\/s00213-006-0358-7","journal-title":"Psychopharmacology (Berl)"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2014.11.015","article-title":"Acute effects of lysergic acid diethylamide in healthy subjects","volume":"78","author":"Schmid Y","year":"2015","unstructured":"Schmid Y, Enzler F, Gasser P, et al.. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015, 78:544-53. 10.1016\/j.biopsych.2014.11.015","journal-title":"Biol Psychiatry"},{"key":"ref46","article-title":"Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers","author":"Schultes E","year":"1998","unstructured":"Schultes E, Hofmann A, Ratsch C. Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers. Healing Arts Press, Rochester, VT; 1998."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/1478-4505-4-13","article-title":"Improving the use of research evidence in guideline development: 1. Guidelines for guidelines","volume":"4","author":"Sch\u00fcnemann HJ","year":"2006","unstructured":"Sch\u00fcnemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 1. Guidelines for guidelines. Health Res Policy Syst. 2006, 4:13. 10.1186\/1478-4505-4-13","journal-title":"Health Res Policy Syst"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.186.6.457","article-title":"Can psychedelics have a role in psychiatry once again?","volume":"186","author":"Sessa B","year":"2005","unstructured":"Sessa B. Can psychedelics have a role in psychiatry once again?. Br J Psychiatry. 2005, 186:457-8. 10.1192\/bjp.186.6.457","journal-title":"Br J Psychiatry"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/pnp.94","article-title":"Are psychedelic drug treatments seeing a comeback in psychiatry?","volume":"12","author":"St John Sessa B","year":"2008","unstructured":"St John Sessa B. Are psychedelic drug treatments seeing a comeback in psychiatry?. Prog Neurol Psychiatry. 2008, 12:5-10. 10.1002\/pnp.94","journal-title":"Prog Neurol Psychiatry"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000774","article-title":"Quantifying the RR of harm to self and others from substance misuse: results from a survey of clinical experts across Scotland","volume":"2","author":"Taylor M","year":"2012","unstructured":"Taylor M, Mackay K, Murphy J, McIntosh A, McIntosh C, Anderson S, Welch K. Quantifying the RR of harm to self and others from substance misuse: results from a survey of clinical experts across Scotland. BMJ Open. 2012, 2:e000774. 10.1136\/bmjopen-2011-000774","journal-title":"BMJ Open"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2016.03.012","article-title":"Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans","volume":"26","author":"Valle M","year":"2016","unstructured":"Valle M, Maqueda AE, Rabella M, et al.. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol. 2016, 26:1161-75. 10.1016\/j.euroneuro.2016.03.012","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1177\/0269881115581980","article-title":"European rating of drug harms","volume":"29","author":"van Amsterdam J","year":"2015","unstructured":"van Amsterdam J, Nutt D, Phillips L, van den Brink W. European rating of drug harms. J Psychopharmacol. 2015, 29:655-60. 10.1177\/0269881115581980","journal-title":"J Psychopharmacol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1159\/000317249","article-title":"Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population","volume":"16","author":"van Amsterdam J","year":"2010","unstructured":"van Amsterdam J, Opperhuizen A, Koeter M, van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res. 2010, 16:202-7. 10.1159\/000317249","journal-title":"Eur Addict Res"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"van Amsterdam J","year":"2011","unstructured":"van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011, 59:423-9. 10.1016\/j.yrtph.2011.01.006","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2013.03.007","article-title":"Physical harm due to chronic substance use","volume":"66","author":"van Amsterdam J","year":"2013","unstructured":"van Amsterdam J, Pennings E, Brunt T, van den Brink W. Physical harm due to chronic substance use. Regul Toxicol Pharmacol. 2013, 66:83-7. 10.1016\/j.yrtph.2013.03.007","journal-title":"Regul Toxicol Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(96)00246-1","article-title":"Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis","volume":"16","author":"Vollenweider FX","year":"1997","unstructured":"Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J. Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology. 1997, 16:357-72. 10.1016\/S0893-133X(96)00246-1","journal-title":"Neuropsychopharmacology"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider FX","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998, 9:3897-902. 10.1097\/00001756-199812010-00024","journal-title":"Neuroreport"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths - United States, 2017-2018","volume":"69","author":"Wilson N","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, Smith H 4th, Davis NL. Drug and opioid-involved overdose deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020, 69:290-7. 10.15585\/mmwr.mm6911a4","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/100558-the-use-of-psychedelics-in-the-treatment-of-medical-conditions-an-analysis-of-currently-registered-psychedelics-studies-in-the-american-drug-trial-registry","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:46:59Z","timestamp":1707508019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/100558-the-use-of-psychedelics-in-the-treatment-of-medical-conditions-an-analysis-of-currently-registered-psychedelics-studies-in-the-american-drug-trial-registry"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.29167","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}